ReviewInternational journal of pharmaceutics: X2025
Nanoparticle-based drug delivery systems: A promising approach for the treatment of liver fibrosis.
Review in International journal of pharmaceutics: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Liver fibrosis: Pathogenesis and innovative nanoparticle-based therapeutic strategies.International journal of pharmaceutics: X · 2026Review
- Current Advances in Liver-Targeted Drug Delivery: Synthetic, Biological, and Biomimetic Platforms.International journal of molecular sciences · 2026Review
- mRNA Therapeutics Beyond Infectious Diseases: Expanding Therapeutic Applications and Future Perspectives.Immunity, inflammation and disease · 2026Review
- Application of Biotechnology in the Synthesis of Nanoparticles-A Review.Molecules (Basel, Switzerland) · 2026Review
- Reengineering statin therapy to protect skeletal muscle: nanocarrier strategies for mitigating mitochondrial dysfunction and myotoxicity.Inflammation and regeneration · 2026Review
- Mechanistic Modulation of Lipopolysaccharide-Induced Hepatic Injury by Chitosan-Coated Selenium Nanoparticles: Targeting the STEAP-3/TLR-4 and IL-17/TRAF-6/HSP-90 Axes.Pharmaceutics · 2026Article
- Hepatotropic Nanomedicine and Targeted Nanocarriers for Liver Diseases and Hepatocellular Carcinoma.International journal of nanomedicine · 2026Review
- Anti-Fibrotic MicroRNA-Based Intervention in Oral Submucous Fibrosis: A Scoping Review.International journal of dentistry · 2026Review
- Carvacrol-Loaded Chitosan Nanoparticles as a Multifunctional Nanotherapeutic Strategy Targeting Oxidative Stress, Inflammation, Apoptosis, and Genotoxicity in Nonalcoholic Fatty Liver Disease.Antioxidants (Basel, Switzerland) · 2025Article
- Smart nanoplatforms for early detection and immune modulation in lung cancer.Frontiers in bioengineering and biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver fibrosis is the predominant pathological feature of chronic liver diseases, affecting the well-being of millions around the world. If not detected and intervened on time during the early stage, liver fibrosis can advance to cirrhosis, hepatic insufficiency, and finally hepatocellular carcinoma, thereby endangering human health seriously. Current pharmacotherapies for liver fibrosis have several limitations, such as a lack of sufficient therapeutic efficacy and the presence of adverse side effects. In light of these challenges, the use of nanoparticles (NPs) as drug delivery systems for liver fibrosis has gained significant traction, owing to their inherent characteristics, including safety, stability, controlled release, and targeted delivery. Compared to conventional dosage forms, nanomedicines exhibit distinct advantages, including enhanced bioavailability and targeted delivery of drugs. The employment of NP systems has quickly gained prominence as a viable strategy for the secure delivery of hepatoprotective nucleic acids and drugs in treating liver fibrosis. This comprehensive review examines the primary categories of NPs and elucidates the targeted mechanisms underlying NP-mediated drug delivery systems specifically designed for addressing liver fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.